Compare AstraZeneca plc (AZN) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Transocean Ltd — how do they compare? AstraZeneca plc trades at $166.71 (market cap $253.13B), while Transocean Ltd trades at $5.33 (market cap $5.88B). The key difference: AstraZeneca plc is far larger — about 43× Transocean Ltd's market cap, and AstraZeneca plc pays a 1.92% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| AZN | RIG | |
|---|---|---|
Market Cap | $253.13B | $5.88B |
Sector | Health | Technology |
52-Week High | $209.48 | $7.58 |
52-Week Low | $137.44 | $2.55 |
Enterprise Value | $279.37B | $10.82B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Transocean Ltd. (RIG) trades at $5.37, up 3.27% today, with a bullish technical signal from moving averages. The company reported a net loss of $2.92 billion in 2025, but revenue grew to $3.97 billion, and recent contract wins, including a $1 billion deal with Equinor, bolster its backlog. The pending merger with Valaris Limited aims to reduce leverage and unlock synergies.
The outlook is mixed; analyst consensus is a Buy with a $7.00 price target, but persistent net losses and high debt pose risks. Upside depends on successful merger integration and improved profitability, while oil price volatility and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
